EP2928300A4 - Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid - Google Patents

Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid

Info

Publication number
EP2928300A4
EP2928300A4 EP13858943.7A EP13858943A EP2928300A4 EP 2928300 A4 EP2928300 A4 EP 2928300A4 EP 13858943 A EP13858943 A EP 13858943A EP 2928300 A4 EP2928300 A4 EP 2928300A4
Authority
EP
European Patent Office
Prior art keywords
methylprolyl
glycyl
treatment
glutamic acid
autism spectrum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13858943.7A
Other languages
German (de)
French (fr)
Other versions
EP2928300A1 (en
Inventor
Lawrence Irwin Glass
Michael John Bickerdike
Michael Frederick Snape
Cogram Patricia Perez De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuren Pharmaceuticals Ltd
Original Assignee
Neuren Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd filed Critical Neuren Pharmaceuticals Ltd
Publication of EP2928300A1 publication Critical patent/EP2928300A1/en
Publication of EP2928300A4 publication Critical patent/EP2928300A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
EP13858943.7A 2012-11-28 2013-11-26 Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid Withdrawn EP2928300A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730829P 2012-11-28 2012-11-28
PCT/US2013/072049 WO2014085480A1 (en) 2012-11-28 2013-11-26 Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid

Publications (2)

Publication Number Publication Date
EP2928300A1 EP2928300A1 (en) 2015-10-14
EP2928300A4 true EP2928300A4 (en) 2016-07-13

Family

ID=50828422

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13858943.7A Withdrawn EP2928300A4 (en) 2012-11-28 2013-11-26 Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid

Country Status (6)

Country Link
EP (1) EP2928300A4 (en)
JP (1) JP2016506380A (en)
AU (1) AU2013352294A1 (en)
BR (1) BR112015012506A2 (en)
CA (1) CA2929286A1 (en)
WO (1) WO2014085480A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180184964A1 (en) 2014-06-30 2018-07-05 Cerora, Inc. System and signatures for a multi-modal physiological periodic biomarker assessment
EP4356964A3 (en) * 2018-08-10 2024-06-19 New York University Use of igf-2 receptor agonist ligands for treatment of angelman syndrome and autism

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094856A2 (en) * 2001-05-24 2002-11-28 Neuronz Limited Gpe analogs and peptidomimetics
US20110112033A1 (en) * 2001-05-24 2011-05-12 Peter David Gluckman Cognitive enhancement and cognitive therapy using glycyl-l-2-methylprolyl-l-glutamic acid
WO2011146109A2 (en) * 2010-05-17 2011-11-24 Mount Sinai School Of Medicine Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580619C (en) * 2004-09-20 2013-11-12 Mount Sinai School Of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
JP2008545697A (en) * 2005-05-23 2008-12-18 ニューレン ファーマシューティカルズ リミテッド Glycyl-prolyl-glutamate analogues
EP2001400B1 (en) * 2006-03-14 2014-05-07 Neuren Pharmaceuticals Limited Oral formulations of glycyl-2-methylprolyl-glutamate
DK2083811T3 (en) * 2006-11-22 2017-01-30 Clinical Res Ass Llc PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
JP2010529128A (en) * 2007-06-08 2010-08-26 マサチューセッツ インスティテュート オブ テクノロジー Treatment of Rett syndrome and other disorders
LT2667715T (en) * 2011-01-27 2017-11-10 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094856A2 (en) * 2001-05-24 2002-11-28 Neuronz Limited Gpe analogs and peptidomimetics
US20110112033A1 (en) * 2001-05-24 2011-05-12 Peter David Gluckman Cognitive enhancement and cognitive therapy using glycyl-l-2-methylprolyl-l-glutamic acid
WO2011146109A2 (en) * 2010-05-17 2011-11-24 Mount Sinai School Of Medicine Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ADRIAN BIRD: "The methyl-CpG-binding protein MeCP2 and neurological disease", BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 36, no. 4, 1 August 2008 (2008-08-01), GB, pages 575 - 583, XP055276490, ISSN: 0300-5127, DOI: 10.1042/BST0360575 *
See also references of WO2014085480A1 *
WENLIN LIAO ET AL: "MeCP2+/ mouse model of RTT reproduces auditory phenotypes associated with Rett syndrome and replicate select EEG endophenotypes of autism spectrum disorder", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 46, no. 1, 31 December 2011 (2011-12-31), pages 88 - 92, XP028467473, ISSN: 0969-9961, [retrieved on 20120109], DOI: 10.1016/J.NBD.2011.12.048 *

Also Published As

Publication number Publication date
JP2016506380A (en) 2016-03-03
AU2013352294A1 (en) 2015-07-09
BR112015012506A2 (en) 2017-07-11
WO2014085480A1 (en) 2014-06-05
CA2929286A1 (en) 2014-06-05
EP2928300A1 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
PL2667715T3 (en) Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
HK1215375A1 (en) Use of akkermansia for treating metabolic disorders
PL2919796T3 (en) Use of akkermansia for treating metabolic disorders
HK1207397A1 (en) Purification of succinic acid
HK1211213A1 (en) Treatment of diseases involving mucin
HK1204573A1 (en) Treatment of inflammatory skin disorders
IL225896A0 (en) Treatment of mecp2-associated disorders
EP2709665A4 (en) Treatment of psoriasis
HK1216504A1 (en) Method for treatment of diseases
IL234796B (en) Compounds for the treatment of ischemia-reperfusion-related diseases
EP2928300A4 (en) Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
GB201218263D0 (en) Treatment of autism
GB201201779D0 (en) Treatment of inflammatory disorders
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201204645D0 (en) Treatment of disease
GB201207363D0 (en) Compounds for the treatment of metabolic disorders
GB201207359D0 (en) Compounds for the treatment of metabolic disorders
GB201221032D0 (en) Method of treatment
GB201207894D0 (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150626

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160609

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 43/46 20060101AFI20160603BHEP

Ipc: C07D 207/00 20060101ALI20160603BHEP

Ipc: A61K 31/41 20060101ALI20160603BHEP

Ipc: A61P 25/28 20060101ALI20160603BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170110